TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23697664

Group type: EXPERIMENTAL
Intervention: Rotavirus gastroenteritis (diagnosed via ICD10 codes and rapid tests)
Number of subjects: 13767

Group type: EXPERIMENTAL
Intervention: Community-acquired rotavirus gastroenteritis
Number of subjects: 13767

Group type: EXPERIMENTAL
Intervention: Hospital-acquired rotavirus gastroenteritis
Number of subjects: 13767

Group type: EXPERIMENTAL
Intervention: Overall incidence rate of hospital-acquired rotavirus gastroenteritis
Number of subjects: 13767

Group type: EXPERIMENTAL
Intervention: Hospitalization duration for community-acquired rotavirus gastroenteritis
Number of subjects: 13767

Group type: EXPERIMENTAL
Intervention: Hospitalization duration for all rotavirus gastroenteritis cases
Number of subjects: 13767

Group type: EXPERIMENTAL
Intervention: Proportion of hospital-acquired rotavirus gastroenteritis in children aged below 18 months
Number of subjects: 13767

Group type: EXPERIMENTAL
Intervention: Proportion of hospital-acquired rotavirus gastroenteritis in children hospitalized for at least 5 days
Number of subjects: 13767
Study: 23697706

Group type: EXPERIMENTAL
Intervention: Very-low-energy diet for 2 months
Number of subjects: 98
Study: 23697705

Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D (25(OH)D) concentrations <10 ng/mL
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D (25(OH)D) concentrations ≥10 to <20 ng/mL
Number of subjects: 240

Group type: COMPARATOR
Intervention: Serum 25-hydroxyvitamin D (25(OH)D) concentrations ≥20 ng/mL (highest category)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Serum concentrations of 25(OH)D
Number of subjects: 240
Study: 23698253

Group type: EXPERIMENTAL
Intervention: Temsirolimus 15 mg IV weekly and Pazopanib 400 mg orally daily
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Temsirolimus 10 mg IV weekly and Pazopanib 200 mg orally daily
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Combination of temsirolimus and pazopanib
Number of subjects: 7
Study: 23700789

Group type: COMPARATOR
Intervention: L-NAME 0 mg.kg-1 (Control)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: L-NAME 1 mg.kg-1
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: L-NAME 2 mg.kg-1
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: L-NAME 4 mg.kg-1
Number of subjects: 27
Study: 23701810

Group type: EXPERIMENTAL
Intervention: Systemic treatment (antidepressants, anticonvulsants, opiates)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Topical treatment with 5% lidocaine medicated plaster
Number of subjects: 84
Study: 23701891

Group type: EXPERIMENTAL
Intervention: Integrative cognitive-affective therapy (ICAT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Enhanced cognitive-behavioral therapy (CBT-E)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both ICAT and CBT-E
Number of subjects: 80
Study: 23702009

Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Implantation (TAVI)
Number of subjects: 405

Group type: COMPARATOR
Intervention: Surgical Aortic Valve Replacement (SAVR)
Number of subjects: 405
Study: 23702951

Group type: EXPERIMENTAL
Intervention: Hypertension intervention via telemedicine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 23703107

Group type: EXPERIMENTAL
Intervention: LA expansion index (calculated as (Volmax - Volmin) × 100%/Volmin)
Number of subjects: 1735

Group type: EXPERIMENTAL
Intervention: LA expansion index
Number of subjects: 1735
Study: 23703364

Group type: EXPERIMENTAL
Intervention: WiCS(®)-LV system (leadless pacing system)
Number of subjects: 3
Study: 23703448

Group type: EXPERIMENTAL
Intervention: Partially covered SEMS (Group A)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Fully covered SEMS with fins (Group B)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Fully covered SEMS with flared ends (Group C)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: CSEMS (all groups combined)
Number of subjects: 55
Study: 23703580

Group type: EXPERIMENTAL
Intervention: GFT505
Number of subjects: 0
Study: 23703638

Group type: EXPERIMENTAL
Intervention: Vacuum-assisted wound closure and mesh-mediated fascial traction (VAWCM)
Number of subjects: 111
Study: 23703723

Group type: EXPERIMENTAL
Intervention: Weight loss intervention (exercise, behavior, and nutrition therapy)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Obese children without weight loss
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 40
Study: 23703925

Group type: EXPERIMENTAL
Intervention: Aspiration thrombectomy
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control (no aspiration thrombectomy)
Number of subjects: 205
Study: 23704672

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Metformin plus rosiglitazone
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Metformin plus intensive lifestyle intervention
Number of subjects: 699

Group type: COMPARATOR
Intervention: All treatment arms
Number of subjects: 699
Study: 23704912

Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy
Number of subjects: 10614

Group type: COMPARATOR
Intervention: No anticoagulant therapy
Number of subjects: 10614

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists
Number of subjects: 10614
Study: 23706709

Group type: EXPERIMENTAL
Intervention: Genetic markers associated with severe asthma exacerbations (51 markers from 17 genes)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Whole genome scan
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Admixture analysis
Number of subjects: 199

Group type: COMPARATOR
Intervention: Previously reported associations of genetic markers with asthma exacerbations
Number of subjects: 199
Study: 23706713

Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Allergen specific serum IgE (sIgE) testing
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) and allergen specific serum IgE (sIgE) testing
Number of subjects: 40
Study: 23706985

Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel at 260 mg/m(2) intravenously every 3 weeks.
Number of subjects: 48
Study: 23707147

Group type: COMPARATOR
Intervention: SCA1 mutation carriers
Number of subjects: 264

Group type: COMPARATOR
Intervention: SCA2 mutation carriers
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: SCA1 and SCA2 mutation carriers
Number of subjects: 264
Study: 23707169

Group type: COMPARATOR
Intervention: F4/AS01 candidate vaccine
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: In vitro stimulation with p17, p24, RT antigens
Number of subjects: 38
Study: 23709304

Group type: EXPERIMENTAL
Intervention: Tapentadol ER
Number of subjects: 1977

Group type: COMPARATOR
Intervention: Oxycodone CR
Number of subjects: 1977
Study: 23710653

Group type: EXPERIMENTAL
Intervention: IV anidulafungin
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: IV anidulafungin followed by oral voriconazole
Number of subjects: 54
Study: 23710698

Group type: EXPERIMENTAL
Intervention: Vaginal dilators, topical corticosteroids, and estrogen for vaginal cGVHD.
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Local immunosuppression and dilators for genital GVHD.
Number of subjects: 1
Study: 23710697

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 0
Study: 23711443

Group type: EXPERIMENTAL
Intervention: Symmetrical dimethylarginine
Number of subjects: 0

Group type: COMPARATOR
Intervention: NT-proBNP
Number of subjects: 0
Study: 23712514

Group type: EXPERIMENTAL
Intervention: Patients discharged to home (HD)
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Patients discharged to other RFs
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Patients discharged to supported housing
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Patients discharged to prison
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Clinicians' predictions about HD
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Variables associated with higher HD likelihood
Number of subjects: 403
Study: 23712839

Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no multivitamin supplementation)
Number of subjects: 0
Study: 23714176

Group type: EXPERIMENTAL
Intervention: Revised Geneva score (RGS)
Number of subjects: 1693

Group type: EXPERIMENTAL
Intervention: Simplified Geneva score (SGS)
Number of subjects: 1693

Group type: COMPARATOR
Intervention: Not applicable (readmission rate)
Number of subjects: 1693
Study: 23714281

Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 29
Study: 23715103

Group type: EXPERIMENTAL
Intervention: Regular plasma treatment for hereditary TTP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 23715577

Group type: EXPERIMENTAL
Intervention: Dasatinib (60 to 120 mg/m(2) once daily)
Number of subjects: 58
Study: 23715608

Group type: EXPERIMENTAL
Intervention: PEEP (positive end-expiratory pressure)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intermediate PEEP level
Number of subjects: 12

Group type: COMPARATOR
Intervention: No PEEP
Number of subjects: 12
Study: 23716272

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 21

Group type: COMPARATOR
Intervention: Dasatinib
Number of subjects: 21

Group type: COMPARATOR
Intervention: Bosutinib
Number of subjects: 21
Study: 23716538

Group type: EXPERIMENTAL
Intervention: Lenalidomide 10 mg/day orally on days 1 - 21 (28-day cycle); melphalan 0.18 mg/kg orally on days 1-4; dexamethasone 40 mg orally on days 1, 8, 15, and 22
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Lenalidomide, melphalan, and dexamethasone
Number of subjects: 25
Study: 23716541

Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m(2))
Number of subjects: 0
Study: 23716765

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Granisetron 1 mg
Number of subjects: 70
Study: 23718677

Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg twice daily
Number of subjects: 35

Group type: COMPARATOR
Intervention: Non-anticoagulated individuals (control group)
Number of subjects: 35
Study: 23719348

Group type: EXPERIMENTAL
Intervention: Efavirenz, didanosine, and lamivudine (combined therapy)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Composite inhibition score
Number of subjects: 49
Study: 23719639

Group type: EXPERIMENTAL
Intervention: Fluticasone/salmeterol
Number of subjects: 2734

Group type: COMPARATOR
Intervention: Budensonide/formoterol
Number of subjects: 2734

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 2734
Study: 23719651

Group type: EXPERIMENTAL
Intervention: Uniblocker® inserted into the endotracheal tube and advanced until the blocker balloon just protruded from the endotracheal tube tip
Number of subjects: 56
Study: 23719719

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (1.8 mg/kg by intravenous infusion every 3 weeks for up to 16 cycles)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 52
Study: 23720019

Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment with full-dose gemcitabine (1 g/m(2) over 30 minutes on days 1, 8, and 15) and oxaliplatin (85 mg/m(2) on days 1 and 15) with radiation therapy (30 Gray in 2-Gy fractions during cycle 1)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment with full-dose gemcitabine, oxaliplatin, and RT
Number of subjects: 68
Study: 23720182

Group type: EXPERIMENTAL
Intervention: Monotherapy for PAH
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Combination therapy for PAH
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: No PAH drugs
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation (OAC)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 4-year survival rate for PAH-CHD
Number of subjects: 104

Group type: COMPARATOR
Intervention: 4-year survival rate for idiopathic PAH (IPAH)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Mean 6-minute walk distance
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Quality of life (EQ-5 D)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: NYHA functional class distribution
Number of subjects: 104
Study: 23720241

Group type: EXPERIMENTAL
Intervention: Objective insomnia defined by polysomnography
Number of subjects: 1042

Group type: EXPERIMENTAL
Intervention: Subjective insomnia symptoms categorized by validated questionnaires
Number of subjects: 1042

Group type: EXPERIMENTAL
Intervention: Subjective DSM-IV insomnia
Number of subjects: 1042

Group type: EXPERIMENTAL
Intervention: Subjective criteria for insomnia
Number of subjects: 1042
Study: 23721329

Group type: EXPERIMENTAL
Intervention: HSCT-treated patients
Number of subjects: 12

Group type: COMPARATOR
Intervention: Natalizumab-treated patients
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: HSCT-treated patients cultured with myelin oligodendrocyte glycoprotein peptides
Number of subjects: 12

Group type: COMPARATOR
Intervention: Natalizumab-treated patients cultured with myelin oligodendrocyte glycoprotein peptides
Number of subjects: 12
Study: 23722308

Group type: EXPERIMENTAL
Intervention: Immunocryosurgery (liquid nitrogen, open spray, 2 × 15 s; day 14) during 5 weeks' imiquimod
Number of subjects: 91
Study: 23723295

Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mitoxantrone
Number of subjects: 0
Study: 23724022

Group type: EXPERIMENTAL
Intervention: sRAGE levels before SBT
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: sRAGE levels at the end of SBT
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Lung aeration loss during successful weaning trial
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: sRAGE levels measured at 4 hours after extubation
Number of subjects: 88
Study: 23724353

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/d
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Duloxetine (any dose)
Number of subjects: 370

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 370
Study: 23724846

Group type: EXPERIMENTAL
Intervention: Lambrolizumab (anti-PD-1) administered intravenously at a dose of 10 mg/kg every 2 or 3 weeks or 2 mg/kg every 3 weeks
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Lambrolizumab (10 mg/kg every 2 weeks)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Lambrolizumab (anti-PD-1)
Number of subjects: 135
Study: 23724867

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (concurrent regimen)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Nivolumab (sequenced regimen)
Number of subjects: 86
Study: 23724881

Group type: EXPERIMENTAL
Intervention: Exercise performed 1 hour after a standardized breakfast (T1h)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Exercise performed 3 hours after a standardized breakfast (T3h)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Exercise in postprandial state
Number of subjects: 16
Study: 23724914

Group type: EXPERIMENTAL
Intervention: Crizotinib
Number of subjects: 0
Study: 23725004

Group type: EXPERIMENTAL
Intervention: AllerT (combination of three COPs selected for undetectable IgE binding)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AllerT4-T5 (second set of COPs with some residual IgE binding)
Number of subjects: 0

Group type: COMPARATOR
Intervention: rBet v 1 (control)
Number of subjects: 0
Study: 23726000

Group type: EXPERIMENTAL
Intervention: 3D-CRT (38.5 Gy in 10 fractions twice daily over 5 days)
Number of subjects: 52
Study: 23726267

Group type: EXPERIMENTAL
Intervention: Tivozanib 1.5mg/d plus temsirolimus 25mg/week
Number of subjects: 27

Group type: COMPARATOR
Intervention: Tivozanib 0.5, 1.0 or 1.5mg/d orally (3 weeks on/1 week off) and temsirolimus 15 or 25 mg/week intravenously
Number of subjects: 27
Study: 23726971

Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m(2) + cisplatin 75 mg/m(2) + cetuximab 250 mg/m(2) (loading dose: 400 mg/m(2))
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard treatment (Platinum/5-fluorouracil plus cetuximab)
Number of subjects: 66
Study: 23728047

Group type: EXPERIMENTAL
Intervention: Controller medicine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Private insurance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caregiver perceived stress
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caregiver depression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Child negative life events
Number of subjects: 0
Study: 23728176

Group type: EXPERIMENTAL
Intervention: ADAR1 knockdown
Number of subjects: 0

Group type: COMPARATOR
Intervention: ADAR1
Number of subjects: 0
Study: 23729198

Group type: COMPARATOR
Intervention: LBBB (Left Bundle Branch Block)
Number of subjects: 65975

Group type: COMPARATOR
Intervention: Intraventricular conduction defect
Number of subjects: 65975

Group type: COMPARATOR
Intervention: RBBB (Right Bundle Branch Block) combined with left anterior fascicular block
Number of subjects: 65975

Group type: COMPARATOR
Intervention: QRS duration ≥ 140 ms in LBBB
Number of subjects: 65975

Group type: COMPARATOR
Intervention: QRS nondipolar voltage (RNDPV)
Number of subjects: 65975

Group type: COMPARATOR
Intervention: QRS/STT angle and ST J-point depression in aVL in LBBB
Number of subjects: 65975

Group type: COMPARATOR
Intervention: RBBB
Number of subjects: 65975
Study: 23729493

Group type: EXPERIMENTAL
Intervention: Adult ADHD Symptoms Rating Scale (ASRS)
Number of subjects: 1171

Group type: EXPERIMENTAL
Intervention: Measurement invariance across gender and age groups
Number of subjects: 1171

Group type: EXPERIMENTAL
Intervention: Total ASRS-ADHD score
Number of subjects: 1171

Group type: EXPERIMENTAL
Intervention: Comparison of scores between genders
Number of subjects: 1171
Study: 23729989

Group type: EXPERIMENTAL
Intervention: Trauma exposure (N = 662, 53%)
Number of subjects: 1263

Group type: COMPARATOR
Intervention: No trauma exposure
Number of subjects: 1263

Group type: EXPERIMENTAL
Intervention: Trauma exposure
Number of subjects: 1263

Group type: EXPERIMENTAL
Intervention: Treatment of presenting anxiety disorder
Number of subjects: 1263
Study: 23730928

Group type: EXPERIMENTAL
Intervention: Clinical Dementia Rating (CDR) by trained community health workers (CHWs)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Physician diagnosis
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic (ROC) curve analysis
Number of subjects: 90
Study: 23731330

Group type: EXPERIMENTAL
Intervention: Maraviroc plus optimized background therapy (OBT)
Number of subjects: 206
Study: 23731760

Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cells (MSCs) from related donors, mean of 6 × 10(5)/kg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control cohort (historic control)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: MSCs treatment
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Immunological analysis post-MSC treatment
Number of subjects: 18
Study: 23731770

Group type: EXPERIMENTAL
Intervention: 124I-iodoazomycin galactopyranoside (124I-IAZGP)
Number of subjects: 10
Study: 23731832

Group type: EXPERIMENTAL
Intervention: Lenalidomide 25mg once daily on days 1-21 of each 28-day cycle for a maximum of 24 months
Number of subjects: 54
Study: 23731998

Group type: EXPERIMENTAL
Intervention: 6% Hydroxyethyl starch (HES) in 0.9% sodium chloride (saline)
Number of subjects: 7000

Group type: COMPARATOR
Intervention: 0.9% sodium chloride (saline)
Number of subjects: 7000
Study: 23732043

Group type: COMPARATOR
Intervention: Antiretroviral therapy (PI and NNRTI)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Nevirapine and efavirenz
Number of subjects: 82

Group type: COMPARATOR
Intervention: Unboosted atazanavir
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Higher CD4+ count
Number of subjects: 82
Study: 23732904

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (4-dose schedule at 0, 1, 2, and 12 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Additional dose of hepatitis B virus (HBV) vaccine
Number of subjects: 0
Study: 23733030

Group type: EXPERIMENTAL
Intervention: SSRIs
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: AD efficacy
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 11
Study: 23733041

Group type: EXPERIMENTAL
Intervention: Two-dose rotavirus (RV) vaccine (RIX4414; GlaxoSmithKline Vaccines)
Number of subjects: 0
Study: 23733198

Group type: EXPERIMENTAL
Intervention: ACE inhibitors (ACEi)
Number of subjects: 1163

Group type: COMPARATOR
Intervention: Non-ACE inhibitors
Number of subjects: 1163
Study: 23733473

Group type: EXPERIMENTAL
Intervention: PaMZ (PA-824-moxifloxacin-pyrazinamide) given at human-equivalent doses 5 days/week for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: RHZ (rifampin-isoniazid-pyrazinamide) given 5 days/week for 8 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both combination regimens (PaMZ and RHZ)
Number of subjects: 0
Study: 23733802

Group type: EXPERIMENTAL
Intervention: Everolimus treatment
Number of subjects: 2

Group type: COMPARATOR
Intervention: No mTOR inhibitor treatment (Control)
Number of subjects: 2
Study: 23733925

Group type: EXPERIMENTAL
Intervention: (99m)Tc-MIP-1427
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: (99m)Tc-MIP-1404
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: (99m)Tc-MIP-1428
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: (99m)Tc-MIP-1405
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: (99m)Tc-labeled PSMA inhibitors
Number of subjects: 0
Study: 23735179

Group type: COMPARATOR
Intervention: Fluticasone furoate (FF) 200 μg
Number of subjects: 96

Group type: COMPARATOR
Intervention: Fluticasone furoate (FF) 400 μg
Number of subjects: 96

Group type: COMPARATOR
Intervention: Fluticasone furoate (FF) 800 μg
Number of subjects: 96

Group type: COMPARATOR
Intervention: Vilanterol (VI) 12.5 μg
Number of subjects: 96

Group type: COMPARATOR
Intervention: Vilanterol (VI) 25 μg
Number of subjects: 96

Group type: COMPARATOR
Intervention: Fluticasone furoate and Vilanterol (FF/VI) 800/50 μg
Number of subjects: 96

Group type: COMPARATOR
Intervention: Vilanterol (VI) 50 μg
Number of subjects: 96
Study: 23735475

Group type: EXPERIMENTAL
Intervention: Transcatheter pulmonary valve replacement using the Melody valve
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics treatment for all patients diagnosed with IE
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: TPV-related infective endocarditis
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Overall clinical outcomes
Number of subjects: 311
Study: 23735702

Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD) at a dose of 40 mg/m² every 28 days for six courses
Number of subjects: 60